Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis

替诺福韦-阿拉芬酰胺 人类免疫缺陷病毒(HIV) 病毒载量 耐受性 养生
作者
Greg L. Plosker
出处
期刊:Drugs [Springer Nature]
卷期号:73 (3): 279-291 被引量:30
标识
DOI:10.1007/s40265-013-0024-4
摘要

The fixed-dose combination of emtricitabine (FTC) 200 mg and tenofovir disoproxil fumarate (TDF) 300 mg (Truvada®), administered orally once daily, is widely used as part of first-line regimens for the treatment of HIV-1 infection. Recently, once-daily administration of FTC/TDF was approved in the USA for pre-exposure prophylaxis in conjunction with safer sex practices to reduce the risk of sexually acquired HIV-1 in high-risk adults who are not infected. To date, results of four large, randomized, double-blind, placebo-controlled, multicentre trials with FTC/TDF as pre-exposure prophylaxis have been published. Three studies showed statistically significant reductions in the number of individuals with emergent HIV-1 infection when FTC/TDF was compared with placebo over the ≈1- to 2-year study periods. Efficacy (i.e. risk reduction relative to placebo) was 44 % in the iPrEx trial in men who have sex with men, 75 % in the Partners PrEP study in heterosexual HIV-1-serodiscordant couples and 62 % in the TDF2 trial in heterosexual men and women. The fourth study (FEM-PrEP) in heterosexual women did not show a statistically significant difference between FTC/TDF and placebo, although low adherence rates reported in this trial may have been a factor. No unexpected adverse events were reported in the trials. However, since pre-exposure prophylaxis involves long-term administration of drugs to healthy individuals, it is important to monitor the long-term safety of FTC/TDF (e.g. renal function, bone mineral density) in this setting. Other notable considerations include adherence, cost and the potential for development of drug resistance. Interim guidelines are available for prescribing FTC/TDF as pre-exposure prophylaxis. If used appropriately in selected high-risk individuals, pre-exposure prophylaxis with FTC/TDF represents an important additional strategy to reduce the spread of HIV-1 infection, which continues to be a significant global concern.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JamesPei应助啥也不会采纳,获得10
1秒前
从容芮应助荷叶采纳,获得10
1秒前
余文君完成签到,获得积分10
4秒前
sissiarno应助边边采纳,获得30
5秒前
5秒前
5秒前
6秒前
故事的小红花完成签到,获得积分10
7秒前
年轻浩然发布了新的文献求助10
9秒前
Cy-coolorgan发布了新的文献求助10
10秒前
荷叶给荷叶的求助进行了留言
10秒前
在水一方应助媛小媛啊采纳,获得10
11秒前
洁净的紫青完成签到,获得积分10
12秒前
研友_VZG7GZ应助依依采纳,获得10
12秒前
yufanhui应助CSC采纳,获得10
12秒前
14秒前
田様应助惠嘟嘟采纳,获得10
16秒前
17秒前
小二郎应助孙同学采纳,获得10
18秒前
从容芮应助KIKI采纳,获得10
18秒前
zhao发布了新的文献求助10
18秒前
zhong完成签到,获得积分10
18秒前
欢喜风发布了新的文献求助10
19秒前
uusmile发布了新的文献求助10
20秒前
comeon发布了新的文献求助20
20秒前
21秒前
酷酷碧发布了新的文献求助10
22秒前
一兜兜糖发布了新的文献求助10
22秒前
23秒前
婷婷大侠完成签到,获得积分10
24秒前
zhong发布了新的文献求助10
24秒前
ZHU009完成签到,获得积分10
24秒前
思源应助nnn采纳,获得10
24秒前
CipherSage应助景清采纳,获得10
25秒前
科目三应助萤火采纳,获得10
25秒前
27秒前
27秒前
小二郎应助开放芷天采纳,获得10
29秒前
研友_LJQev8发布了新的文献求助10
29秒前
29秒前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3051580
求助须知:如何正确求助?哪些是违规求助? 2708899
关于积分的说明 7414809
捐赠科研通 2353209
什么是DOI,文献DOI怎么找? 1245431
科研通“疑难数据库(出版商)”最低求助积分说明 605674
版权声明 595846